F.I.T Group JSC

F.I.T Group JSC maintains a capital structure with a debt-to-equity ratio of 0.43, indicating a relatively balanced leverage position. The company's liquidity is assessed as medium, with a current ratio of 2.82, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 0.0103 and a return on assets (ROA) of 0.005, both below the typical thresholds for strong performance in the pharmaceutical industry. The company's gross profit margin is 18.66% (386,808,823,810 / 2,073,187,800,370), and its operating margin is 5.30% (109,866,903,000 / 2,073,187,800,370), which are below the median for the industry. These figures suggest that the company is not generating returns at a level that would be considered robust for its sector. The company's revenue is distributed across four business segments: pharmaceuticals, FMCG, real estate, and agriculture. The pharmaceutical business is the primary revenue driver, but the company also has exposure to FMCG, which includes bottled natural alkaline mineral water and non-alcoholic beverages, as well as cosmetics. The real estate and agricultural segments contribute to the company's diversification but are not the primary focus. The geographic exposure is primarily within Vietnam, with no significant international operations disclosed. The company's growth trajectory is modest, with a current year outlook for revenue growth and a next year outlook that is not significantly different. The company's free cash flow is negative at -50,461,695,490, and capital expenditures are substantial at -264,287,769,780, indicating ongoing investment in operations. The company's operating cash flow is positive at 1,493,035,896,010, which supports its operational needs but does not fully offset the capital outlay. Risk factors include the company's liquidity position, as noted by the negative net cash after debt. The risk assessment indicates a low potential for dilution, but the company's capital structure and cash flow dynamics suggest that it may need to raise additional capital in the future. The company's recent financial filings do not indicate any major events that would significantly alter its risk profile, but the ongoing investment in capital expenditures suggests a focus on long-term growth. Recent events, as disclosed in the company's financial filings, do not include any major corporate actions or significant changes in business strategy. The company's focus remains on its core pharmaceutical business, with continued investment in FMCG and other segments. The company's financial health is supported by its operating cash flow, but the negative free cash flow and substantial capital expenditures indicate that the company is reinvesting heavily in its operations.